Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The Methodist Hospital System has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners across 3 art units, indicating broad examiner distribution with some concentration at the technical-group level.
TRUONG, QUANGLONG N is the busiest examiner, with 1 pending matter. Portfolio management should emphasize consistent claim and disclosure positions while allowing for differences in examiner treatment across the 3 art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
| CESARE, JOSEPH DAVID | 1 | — | — |
| SISON, CHRISTINE ANDREA PAN | 1 | 32.7% | +40.7% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566129 | DKK1/HLA-A2 BINDING MOLECULES AND METHODS OF THEIR USE | CESARE, JOSEPH DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18915635 | IMPLANTABLE NANOCHANNEL DELIVERY DEVICES | TRUONG, QUANGLONG N | — |
| 18288019 | SYSTEMS AND METHODS FOR IMPROVING CEREBROSPINAL FLUID (CSF) DRAINAGE | SISON, CHRISTINE ANDREA PAN | — |
| 18020502 | BECLIN 2 AND USES THEREOF FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES | WANG, CHANG YU | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1615 | 1 |
| 3700 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18915635 | IMPLANTABLE NANOCHANNEL DELIVERY DEVICES | TRUONG, QUANGLONG N | 1615 | Other | Non-Final OA | — | Pending | Oct 15, 2024 |
| 18566129 | DKK1/HLA-A2 BINDING MOLECULES AND METHODS OF THEIR USE | CESARE, JOSEPH DAVID | 1675 | §101§102§103§112Other | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18288019 | SYSTEMS AND METHODS FOR IMPROVING CEREBROSPINAL FLUID (CSF) DRAINAGE | SISON, CHRISTINE ANDREA PAN | 3700 | §103 | Final Rejection | — | Pending | Oct 23, 2023 |
| 18020502 | BECLIN 2 AND USES THEREOF FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES | WANG, CHANG YU | 1675 | §112 | Final Rejection | — | Pending | Feb 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Methodist Hospital System has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Quanglong N Truong has the most, with 1 of The Methodist Hospital System's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
